Bevacizumab Against Recurrent Retinal Detachment (BEARRD)
Retinal Detachment, Proliferative Vitreoretinopathy
About this trial
This is an interventional prevention trial for Retinal Detachment focused on measuring Retinal detachment, Proliferative vitreoretinopathy
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Eyes with rhegmatogenous retinal detachment
Exclusion Criteria:
- Presence of PVR
- Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
- Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
- Secondary retinal detachment repair
- Use of silicone oil as tamponade agent
- Patients less than 18 years of age
- Pregnancy
- Known allergy or contraindication to intravitreal bevacizumab
Sites / Locations
- University of Wisconsin
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Bevacizumab
Chart review
Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.